NCT02656017View on ClinicalTrials.gov

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

June 27, 2016

Primary Completion Date

December 7, 2020

Study Completion Date

December 7, 2020

Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
DRUG

Metformin

Monitoring of tolerability and symptoms.

OTHER

Placebo

Monitoring of tolerability and symptoms.

Trial Locations (2)

21201

University of Maryland Medical Center, Baltimore

02111

Tufts Medical Center, Boston

All Listed Sponsors
collaborator

Tufts Medical Center

OTHER

collaborator

University of Maryland, Baltimore

OTHER

collaborator

University of Southern California

OTHER

collaborator

United States Department of Defense

FED

lead

Kyongtae Ty Bae, M.D., Ph.D.

OTHER

NCT02656017 - Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter | Biotech Hunter